AnaptysBio (ANAB) CFO reports RSU vesting, sale, options transactions

Rhea-AI Filing Summary

AnaptysBio, Inc. Chief Financial Officer Dennis Mulroy reported equity compensation activity and a related share sale. On January 6, 2026, 5,245 restricted stock units settled into common stock, and he then beneficially owned 19,575 common shares. On January 7, 2026, he sold 1,908 common shares at $45.11 per share to cover tax withholding tied to the RSU vesting, which the company notes was a non-discretionary sell-to-cover transaction, leaving him with 17,667 common shares.

On January 6, 2026, he also received new grants of 21,400 restricted stock units and 29,000 stock options with a $43.91 exercise price. The 21,400 RSUs vest 25% annually starting January 6, 2027, and the option vests 25% on January 6, 2027, then monthly in equal installments until fully vested, in each case contingent on continued service.

Insider Trade Summary

Net Seller: 1,908 shares ($86,070)

Net Sell 5 txns

Insider MULROY DENNIS

Role CHIEF FINANCIAL OFFICER

Sold 1,908 shs ($86K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,908	$45.11	$86K
Exercise	Restricted Stock Unit	5,245	$0.00	--
Grant/Award	Restricted Stock Unit	21,400	$0.00	--
Grant/Award	Stock Option (right to buy)	29,000	$0.00	--
Exercise	Common Stock	5,245	$0.00	--

Holdings After Transaction: Common Stock — 17,667 shares (Direct); Restricted Stock Unit — 5,245 shares (Direct); Stock Option (right to buy) — 29,000 shares (Direct)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MULROY DENNIS

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		M		5,245	A	(1)	19,575	D
Common Stock	01/07/2026		S(2)		1,908	D	$45.11	17,667	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	01/06/2026		M			5,245	(3)	(3)	Common Stock	5,245	$0	5,245	D
Restricted Stock Unit	(1)	01/06/2026		A		21,400		(4)	(4)	Common Stock	21,400	$0	21,400	D
Stock Option (right to buy)	$43.91	01/06/2026		A		29,000		(5)	01/05/2036	Common Stock	29,000	$0	29,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

3. The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

4. The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

5. The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Eric Loumeau, Attorney-in-Fact	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did AnaptysBio (ANAB) CFO Dennis Mulroy report in this Form 4?

The filing reports RSU vesting into 5,245 AnaptysBio common shares, a 1,908-share sale to cover tax withholding, and new grants of 21,400 RSUs and 29,000 stock options.

How many AnaptysBio common shares did the CFO sell and at what price?

Dennis Mulroy sold 1,908 AnaptysBio common shares at a price of $45.11 per share to cover tax withholding obligations from RSU vesting.

Was the AnaptysBio CFO’s stock sale a discretionary transaction?

No. The footnote explains the 1,908-share sale was executed to satisfy tax withholding obligations via a sell-to-cover arrangement and did not represent a discretionary transaction by the CFO.

What new equity awards did the AnaptysBio CFO receive in this filing?

On January 6, 2026, he received 21,400 restricted stock units and a stock option for 29,000 shares of common stock with a $43.91 exercise price.

How do the new AnaptysBio RSUs granted to the CFO vest?

The 21,400 RSUs vest as to 25% of the total RSUs annually beginning on January 6, 2027, until fully vested, subject to his continued service to the company on each vesting date.

What is the vesting schedule for the AnaptysBio CFO’s new stock option?

The 29,000-share stock option vests 25% on January 6, 2027, and the remaining shares vest in equal monthly installments (1/48 of the total) until fully vested, conditioned on continued service.

How many AnaptysBio common shares did the CFO hold after these transactions?

After the reported transactions, Dennis Mulroy beneficially owned 17,667 shares of AnaptysBio common stock directly.